Kura Oncology grants director 35,000 stock options
Kura Oncology reported that director Mary T. Szela received an option grant to purchase 35,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Kura Oncology reported that director Mary T. Szela received an option grant to purchase 35,000 shares of common stock. The option has an exercise price of $8.77 per share and expires on June 3, 2036. It vests in full on the one-year anniversary of the grant date, and following this award she holds 35,000 options directly.
Insider Trade Summary
Grant/Award: 35,000 shares
Grant/Award
1 txn
Insider
Szela Mary T
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option to purchase common stock | 35,000 | $0.00 | $0.00 |
Holdings After Transaction:
Option to purchase common stock — 35,000 contracts (Direct)
Footnotes (1)
- F1. This option vests in full on the one year anniversary of the date of grant.
Key Figures
Option grant size: 35,000 options
Exercise price: $8.77 per share
Underlying shares: 35,000 shares
+3 more
6 metrics
Option grant size
35,000 options
Director Mary T. Szela grant on June 4, 2026
Exercise price
$8.77 per share
Strike price for option to purchase common stock
Underlying shares
35,000 shares
Common stock underlying the granted option
Expiration date
June 3, 2036
Option expiration for Mary T. Szela grant
Vesting schedule
100% after one year
Option vests in full on one-year anniversary of grant
Post-grant derivative holdings
35,000 options
Total options held directly after this transaction
Key Terms
Option to purchase common stock, exercise price, expiration date, vests in full, +1 more
5 terms
Option to purchase common stock financial
"security_title: Option to purchase common stock"
exercise price financial
"conversion_or_exercise_price: 8.7700"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-03T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vests in full financial
"This option vests in full on the one year anniversary"
Form 4 financial
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did KURA director Mary T. Szela report on this Form 4?
Mary T. Szela reported receiving an option grant for 35,000 Kura Oncology common shares. The award is a compensation-related grant, not an open-market stock purchase or sale, and gives her the right to buy shares at a fixed price in the future.
How many Kura Oncology (KURA) options were granted to Mary T. Szela?
She was granted options for 35,000 shares of Kura Oncology common stock. These options represent her entire reported derivative position after the transaction, according to the filing’s post-transaction holdings disclosure.
What is the exercise price of Mary T. Szela’s new KURA stock options?
The options have an exercise price of $8.77 per share. This means she can buy Kura Oncology common stock at $8.77 once the options vest and before they expire, regardless of the market price at that time.
When do Mary T. Szela’s Kura Oncology options vest and expire?
The option vests in full on the one-year anniversary of the grant date. It carries an expiration date of June 3, 2036, giving a long window to exercise once vested, according to the Form 4 disclosure and related footnote.
AI-generated analysis. How Rhea-AI works. Not financial advice.
